OptimizeRx Conference Call Announcement for Q3 Results

OptimizeRx Plans Q3 2025 Conference Call
OptimizeRx Corp. (Nasdaq: OPRX), a company dedicated to providing cutting-edge healthcare technology solutions, is set to hold a conference call on November 6, 2025, at 4:30 p.m. Eastern Time. This call will focus on the company’s financial results for the third quarter, which ended on September 30, 2025. Interested participants can expect the financial details to be released in a statement prior to the call.
About the Conference Call
The management team at OptimizeRx will lead the conference call, which will also include a segment for audience questions and answers. Here are the essential details:
Conference Call Details
- Date: November 6, 2025
- Time: 4:30 p.m. ET (1:30 p.m. PT)
- Toll-Free Number: 1-844-825-9789
- International Number: 1-412-317-5180
- Conference ID: 10203796
It is recommended for participants to call or log in at least five minutes before the scheduled start time.
Accessing the Webcast
A live webcast will also be available for those who prefer an online format. The replay of the call can be accessed for 12 months via the Investors section of the OptimizeRx website.
Innovative Solutions by OptimizeRx
OptimizeRx is transforming the way life science brands connect with healthcare professionals (HCPs) and patients through its innovative technology. The company’s platform features tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT). These skills enable healthcare brands to deliver timely and localized messaging, improving market engagement.
Commitment to Patient-Centric Solutions
Central to OptimizeRx’s mission is the commitment to privacy-safe, patient-centric solutions. Every interaction is designed with the aim to positively influence patient outcomes by ensuring timely access to life-changing therapies. By collaborating with leading pharmaceutical and life science companies, OptimizeRx is actively working to create a healthier future through improved healthcare communication.
Contact Information
For any inquiries related to the conference call or to learn more about OptimizeRx's services, please reach out to:
OptimizeRx Contact
Andy D’Silva, Chief Business Officer,
adsilva@optimizerx.com
Investor Relations Contact
Steven Halper,
LifeSci Advisors, LLC,
shalper@lifesciadvisors.com
Frequently Asked Questions
What is the purpose of the conference call?
The conference call aims to discuss the financial results of OptimizeRx for the third quarter of 2025.
When is the conference call scheduled?
The call is set for November 6, 2025, at 4:30 p.m. ET.
How can I access the conference call?
You can access it through a toll-free number or the provided international number. Details can be found above.
What technology does OptimizeRx offer?
OptimizeRx provides technology solutions that enhance communication between life sciences brands and healthcare professionals, focusing on patient engagement.
How can I contact OptimizeRx for more information?
Contact Andy D’Silva at adsilva@optimizerx.com for inquiries regarding OptimizeRx.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.